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Efficacy of gemcitabine in patients with non-resectable pancreatic cancer:
prospective clinical studies
Tadeusz Popiela, Bogus∏aw K´dra, Marek Sier˝´ga
A i m.  Cancer of the pancreas continues to be a leading cause of cancer deaths. The aim of our study was to assess the effect
of gemcitabine-based chemotherapy regimen on treatment outcomes in patients with non-resectable pancreatic cancer.
M a t e r i a l  a n d  m e t h o d s. Sixty-one patients were qualified on the basis of intraoperative tumour staging. On day 10 fol-
lowing surgery patients were randomised to form a treatment group receiving 1000 mg/m2 gemcitabine (group I) and a con-
trol group (group II).
R e s u l t s.  No statistically significant differences were seen between the groups regarding clinical and pathological characte-
ristics. A positive response to chemotherapy was noted in 11 (35.5%) of the patients so treated. An objective positive respon-
se (reduction in tumour size or no change) was confirmed in follow-up diagnostic imaging examinations in 7 patients in gro-
up I and 1 patient in group II (p<0.05). The percentage of patients whose tumours increased in size by less than 10% from ba-
seline was considerably higher in the treatment group (62.9%) than in the control group (33.3%), at p<0.01. Group
I patients also required less use of analgesics, more often experienced no weight loss and were clinically better off than the con-
trols in group II (p<0.01). Mean survival time of gemcitabine-treated patients was 6.7 months, which was significantly lon-
ger than in the control group (4.5 months, p<0.01). Side effects, mostly transient leukopenia, were observed in 22% of patients
during the study.
C o n c l u s i o n.  On the basis of these results, the authors recommend gemcitabine-based chemotherapy regimens as the tre-
atment of choice in non-resectable pancreatic carcinoma.
Ocena skutecznoÊci gemcytabiny w leczeniu chorych z nieresekcyjnym rakiem trzustki:
prospektywne badania kliniczne
Rak trzustki pozostaje nadal jednà z wiodàcych przyczyn zgonów na nowotwory z∏oÊliwe. Celem niniejszej pracy by∏a ocena
wp∏ywu chemioterapii, opartej na gemcytabinie, na wyniki leczenia chorych z nieresekcyjnym rakiem trzustki. W oparciu
o Êródoperacyjnà ocen´ stopnia zaawansowania nowotworu do badania w∏àczono 61 chorych. W 10 dobie po zabiegu ope-
racyjnym chorych randomizowano do grupy terapeutycznej, otrzymujàcej gemcytabin´ w iloÊci 1000 mg/m2 (grupa I) lub gru-
py kontrolnej (grupa II). Nie stwierdzono istotnych statystycznie ró˝nic, dotyczàcych cech kliniczno-patologicznych mi´dzy ba-
danymi grupami. U 11 (35.5%) chorych, otrzymujàcych chemioterapi´, stwierdzono cechy odpowiedzi pozytywnej. Obiektyw-
nà odpowiedê pozytywnà w postaci cz´Êciowej regresji lub stabilizacji wymiarów guza stwierdzono w kontrolnych badaniach
obrazowych u 7 chorych w grupie I i 1 chorego w grupie II (p<0.05). Odsetek chorych, u których stwierdzono progresj´ ma-
sy guza poni˝ej 10% stanu wyjÊciowego, w grupie otrzymujàcej chemioterapi´ by∏ znacznie wy˝szy (62.9%), w porównaniu do
grupy kontrolnej (33.3%); p<0.01. Chorzy w grupie I wymagali stosowania mniejszej iloÊci Êrodków przeciwbólowych, cz´-
Êciej utrzymywali sta∏à wag´ cia∏a oraz byli w lepszym stanie klinicznym w porównaniu do grupy II (p<0.01). Âredni czas prze-
˝ycia chorych otrzymujàcych gemcytabin´ wynosi∏ 6.7 miesiàca i w porównaniu z grupà kontrolnà (4.5 miesiàca) by∏ znaczà-
co d∏u˝szy (p<0.01). W czasie badania objawy uboczne chemioterapii obserwowano u 22% chorych i dotyczy∏y one g∏ównie
przejÊciowej leukopenii. Na podstawie uzyskanych wyników autorzy rekomendujà stosowanie chemioterapii, opartej na
gemcytabinie, jako leczenie z wyboru w przypadku nieresekcyjnych raków trzustki.
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Introduction
Cancer of the pancreas accounts for 5-8% of all cancers
and is the fifth most frequent cause of cancer-related de-
aths in Western European countries and the USA [1-3].
Since 1960, the pancreatic cancer mortality rate in Poland
has been growing to reach 13.1 per 100.000 in 1996 [4].
This form of cancer is usually diagnosed at an advanced
stage so that only 20-30% of patients are qualified for re-
section surgery while others can only benefit from palliati-
ve treatment that ameliorates the clinical symptoms [3,
5-7]. Palliative treatment will usually make possible a tem-
porary remission of a few months' duration in about 30%
of patients. Mean survival time of patients with an advan-
ced pancreatic carcinoma is 3-6 months, with 90% not
surviving beyond one year since diagnosis. Chemotherapy
regimens used to date for patients with advanced pancre-
atic cancer, based on 5-fluorouracil, adriamycin, streptozo-
cin or mitomycin C, have produced a positive clinical re-
sponse only in 4-5% of patients [8-10]. At the same time,
literature on gemcitabine published in recent years sugge-
sts better treatment outcomes in advanced pancreatic can-
cer with gemzar-based chemotherapy [11-14].
The aim of this study was to evaluate the effect of
gemcitabine on clinical outcomes in patients with non-
-resectable cancer of the pancreas.
Patients and methods
The participants of the study were patients with a confirmed
diagnosis of pancreatic cancer who underwent surgery at the
1st Chair of General Surgery CM UJ between September 1996
and December 1998. In all patients the diagnosis and local sta-
ging data were verified intraoperatively during a laparotomy
procedure. The following criteria were used in qualifying pa-
tients for treatment:
1. Histopathologically confirmed adenocarcinoma of the pan-
creas
2. Intraoperatively confirmed non-resectable tumour (stage
IV according to TNM/UICC)
3. Patient age: 18-70 years
4. Clinical status >50 pts (Karnofsky scale)
5. Plasma bilirubin <32 mmol/l
6. AspAT, AlAT <80 U/l
7. Plasma albumin >28 g/l
8. Leukocyte count >4000, platelet count >100,000/mm3
9. Absence of signs of cardiovascular or respiratory insuffi-
ciency
10. Informed consent to participate obtained from the patient
Patients who met all the above criteria were randomised in-
to two clinical groups: Group I, which received gemcitabine-
-based palliative chemotherapy, and Group II, receiving only
symptomatic treatment.
Palliative chemotherapy was based on the following regi-
men: starting from the tenth day following surgery, 1000 mg/m2
gemcitabine was given in a continuous intravenous infusion over
30 minutes, once a week over 7 weeks. After a week's break,
treatment was continued for another 3 weeks. Treatment outco-
mes were evaluated in both groups at 12 weeks after surgery. If
a positive response was observed, treatment was continued until
the disease was in progress, toxic side effects occurred or the pa-
tient withdrew consent to further treatment.
Examinations carried out in both groups every week inclu-
ded body weight measurements and toxicity assessment based on
the ECOG scale. Additionally, the tumour mass was monito-
red using imaging diagnostics (CT, USG): tumour size was me-
asured before the surgery and at 12 weeks after the surgery.
Quality of life was also assessed using general status data (based
on the Karnofsky scale) and the amount and type of analgesic
medications required. A positive clinical response was defined as
an improvement of one of the parameters continuing over 4
weeks without deterioration in any other parameter, and in the
setting of increasing tumour size. An objective positive respon-
se was defined as stabilisation or reduction of tumour size seen
in the follow-up imaging exam.
The results were analysed using the Statistica 5.5 software
package (StatSoft). Variables were tested using the chi-squared
test, long-term survival in the study groups was evaluated by
the Kaplan-Meier method and compared using the log-rank
test. The value of p=0.05 was regarded as statistically significant.
Results
Sixty-one patients treated for pancreatic cancer betwe-
en September 1996 and December 1998 were qualified
for the study (32 men, 29 women). Demographic charac-
teristics are presented in Table I. Following intraoperati-
ve clinical staging of the tumour, the patients were rando-
mised into two clinical groups.
Tab. I. Demographic data breakdown per study group
Gemcitabine Controls
n=31 n=30 P
Gender
F 14 15 NS
M 17 15
Tumour location
Head 19 18 NS
Body 9 10
Tail 3 2
TNM classification stage
IVA 12 14 NS
IVB 19 16
Type of surgical procedure 
Choledochoduodenostomy + gastroenterostomy 19 18
Gastroenterostomy 3 1 NS
Laparotomy 9 11
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Group I (gemcitabine group) consisted of 31 pa-
tients (14 women and 17 men) aged 59.9±12.3 years. 19
patients had carcinoma of the pancreatic head, 9 had
a lesion in the body and the remaining three, in the tail of
the pancreas. 12 patients had a stage IVA tumour and
the remaining 19 had a stage IVB tumour, according to
the TNM/UICC classification (1997) [15]. Bypass ana-
stomoses (choledochoduodenostomies and gastroente-
rostomies) were formed in the 19 patients with carcinoma
of the head, 3 patients had only gastrostomy performed
and in the remaining 9 the surgical intervention was limi-
ted to an exploratory laparotomy.
The second group (control group) consisted of 30
patients (15 women and 15 men) aged 60.2±11.3 years.
Location of the tumour was similar to that observed in
group I, with involvement of the pancreatic head in 18 pa-
tients, body in 10 and tail in the remaining 2. Fourteen pa-
tients had a stage IVA tumour, and the remaining 16, an
IVB tumour. The number and type of surgical procedures
performed were similar to those carried out in group
I patients. There were no statistically significant diffe-
rences between the groups regarding demographics, tu-
mour stage and type of surgical intervention (Tab. I).
Following a course of 10 cycles of gemcitabine treat-
ment, a positive response was observed in 11 (35.5%) pa-
tients. An objective positive response was noted in 7 pa-
tients and the remaining 4 showed only clinically positive
response, that is improvement in overall clinical status, di-
sappearance of pain and stabilisation of body weight. The
remaining 20 patients (64.5%) showed no signs of a posi-
tive response (Tab. II).
There were no differences in age or gender between
those patients on chemotherapy who responded and those
who did not. A relatively higher percentage of responders
was seen with carcinomas of the body and tail (7/13) com-
pared to carcinomas of the pancreatic head (4/19). Howe-
ver, this finding was not statistically significant. No relation-
ship was also established between the TNM/UICC tumour
stage and a positive response, which was observed sym-
metrically in patients with IVA and IVB stage tumours.
In 92% (57/61) of the patients, tumour size was objec-
tively determined at the follow-up examination. In the re-
maining patients, adequate tumour images could not be
obtained due to technical difficulties so that a reliable as-
sessment was impossible. Table III shows the results of
the measurement. In group I, reduction or stabilisation
of the size of the tumour mass was observed in 25.9% (7)
of the patients, compared to 3.3% (1) in the control group
and these between-group differences were statistically si-
gnificant (p<0.05). Reduction of tumour size was seen in
2 patients in group I, which made it possible to perform
palliative resection of the body and tail of the pancreas fol-
lowing 6-month chemotherapy in one of them. Increase in
tumour size was seen in the majority of the patients in
both groups: 74% (20) of patients in the gemcitabine gro-
up and 96.7% (29) of patients in the control group, but the
„profile” of disease progression was different. In group
I, an increase in tumour size of more than 10% from base-
line was seen in 11.1% (3) of patients, compared to as
many as 63.4% (19) of patients in group II. More patients
in group I (62.9%) had an increase in tumour size of less
than 10% above baseline than in group II (33.3%). These
differences were also statistically significant (p<0.01).
Tab. III. Change in tumour size (ultrasound, CT)
Size of tumour mass Gemcitabine Controls
n=27 n=30 P
Reduction 2 (7.4%) 0 (0%) <0.05
Stabilisation 5 (18.6%) 1 (3.3%)
Increase 20 (74.0%) 29 (96.7%)
< 10% 17 (62.9%) 10 (33.3%) <0.01
> 10% 3 (11.1%) 19 (63.4%)
The changes in the size of tumour mass correlated
with the clinical picture in both groups, as shown in Table
IV. Overall clinical status, assessed using the Karnofsky
scale, was considerably better in the patients receiving
Gemzar. More than 51% (16) of the patients in this gro-
up scored above 70 points, compared to 17% (5) in the
control group. Also, in the control group more than 83%
(25) scored below 70 points (p<0.01). Weight loss was
also markedly faster among patients in the control group
(93% vs 64%) compared to the gemcitabine-treated pa-
Tab. II. Response to chemotherapy (n=31)
Positive response No P
n = 11 response
objective clinical n = 21
n=6 n=4
Gender
F 3 2 10 NS
M 4 2 11
Mean age (years) 59.2 62.1 58.2 NS
Tumour location
Head 2 2 15 NS
Body or tail 5 2 6
TNM/UICC stage
IVA 4 2 7
IVB 3 2 14 NS
Fig. 1. Long-term survival in the study groups
months
gemza
controls
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tients (p<0.01). Patients in the control group also re-
quired more analgesics than those in group I (p<0.01)
and the proportion of narcotic drugs among analgesics
was higher in the control group, too. Mean survival time
in group I was 6.7 months and was longer by more than 2
months than in group II (4.5 months, p<0.01). Mean su-
rvival time was 11.1 months in patients with a positive
response. The longest survival time was seen in the pa-
tient in whom, following 6-month chemotherapy, palliati-
ve resection surgery was performed.
Tab. IV. Quality of life comparison
Gemcitabine Controls P
n=31 n=30
Use of analgesic medications 12 23 <0.01
non-narcotic 9 13
narcotic 3 10
General status (Karnofsky scale) <0.01
<70 pts 15 25
>70 pts 16 5
Body weight <0.01
stable 11 2
lower 17 18
cachexia 3 10
Mean survival time
(months) 6.7 4.5 <0.01
(11.1)*
* Responding patients
The assessment of toxicity of the gemcitabine treat-
ment revealed only minor side effects (Table V), with
transient leukopenia in 22.5% of the patients, thrombocy-
topenia in 19.3%, anaemia in 12.9%, nausea and vomiting
and transient peripheral oedema in 19.3% of the gemcita-
bine-treated patients.
Tab. V. Chemotherapy toxicity assessment (WHO criteria)
Parameter I° II° III° VI° %
Leukopenia 4 2 1 - 22.5
Thrombocytopenia 2 3 1 - 19.3
Anaemia 2 1 1 - 12.9
Nausea/vomiting 3 2 1 - 19.3
Diarrhoea 1 1 - - 6.4
Oedema 2 3 1 - 19.3
Discussion
Gemcitabine (gemcitabine hydrochloride) is a new cytosta-
tic of the antimetabolite group. It is a deoxycytidine analo-
gue which exhibits cytostatic activity following transforma-
tion to active metabolites. Deoxycytidine kinase mediates
the phosphorylation of gemcitabine to bi- and triphospha-
tes. These block DNA synthesis and error correction thro-
ugh inhibitory action on DNA polymerase and ribo-
nucleotide reductase. Clinical studies carried out to date
have demonstrated that gemcitabine is effective in patients
with non-small cell carcinoma of the lung and other solid
tumours, mainly carcinomas of the breast and ovary [8,
16]. Since the mid-1990's it has also been approved in the
USA for palliative treatment of pancreatic carcinoma.
Prospective randomised clinical studies of gemcitabi-
ne in a homogeneous group of patients with inoperable
pancreatic cancer minimise the possibility of an error in
evaluating the efficacy of gemcitabine. Preoperative
staging of pancreatic cancer is not fully reliable despite
the use of modern diagnostic procedures [18, 19]. It was
for this reason that only patients in whom intraoperative
staging was carried out were qualified for the study.
Our results confirm earlier reports by other authors
that gemcitabine is highly effective in the treatment of
pancreatic cancer [11-14]. A positive response noted in
more than 30% of all patients receiving Gemzar represen-
ted a much higher percentage than has been observed
with other chemotherapy regimens [8-10].
Partial regression of the tumour in 2 of the patients
(7.4%), confirmed by follow-up imaging examinations,
made it possible to carry out a palliative resection proce-
dure in one of them later on. Even though the percentage
of patients with tumour size reduction was small, it indica-
tes potential benefits of using Gemzar as a neoadjuvant in
the treatment of locally advanced pancreatic carcinoma.
Despite signs of progression of disease in 74% of the pa-
tients receiving chemotherapy, the increase in tumour si-
ze was usually much less marked than in the control gro-
up. A slowing down of the rate of disease progression,
seen in most of the patients receiving Gemzar, led to
a considerable improvement in their overall clinical status.
Stabilisation of body weight and reduction of the amount
of analgesics required, together with the improvement
in general status, are indicative of high palliative efficacy
of the chemotherapy regimen under study. Thus, even in
the setting of progressing cancer, patients can be offe-
red effective palliative management.
Prolongation of patient survival time is the most ob-
jective criterion of treatment efficacy. Our analysis showed
a significant lengthening of mean survival time in the gem-
citabine group compared to the control group (6.7 vs 4.5
months), which concurs with the findings of other authors
[8, 10-14]. Mean survival time was even longer (11.1 mon-
ths) among the 11 (32%) responding patients.
Untoward side effects associated with gemcitabine
are not different from those produced by other cytostatics
medications. Minor bone marrow suppression seen in
22.5% of the patients indicates that the chemotherapy
treatment under study is considerably safe.
Conclusions
On the basis of their results, the authors recommend
gemcitabine-based chemotherapy as the treatment of
choice for patients with non-resectable pancreatic can-
cer. The high efficacy of the Gemzar treatment in the
group of patients in this study prompted the authors to
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undertake another clinical study where gemcitabine is
used as supplementary treatment following resection of
pancreatic carcinoma in monotherapy or combination
therapy with leucovorin and cisplatin.
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